These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 18283321)

  • 1. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
    Tamura K; Okamoto I; Kashii T; Negoro S; Hirashima T; Kudoh S; Ichinose Y; Ebi N; Shibata K; Nishimura T; Katakami N; Sawa T; Shimizu E; Fukuoka J; Satoh T; Fukuoka M;
    Br J Cancer; 2008 Mar; 98(5):907-14. PubMed ID: 18283321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
    Asahina H; Yamazaki K; Kinoshita I; Sukoh N; Harada M; Yokouchi H; Ishida T; Ogura S; Kojima T; Okamoto Y; Fujita Y; Dosaka-Akita H; Isobe H; Nishimura M
    Br J Cancer; 2006 Oct; 95(8):998-1004. PubMed ID: 17047648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
    Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
    Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
    Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
    Inoue A; Suzuki T; Fukuhara T; Maemondo M; Kimura Y; Morikawa N; Watanabe H; Saijo Y; Nukiwa T
    J Clin Oncol; 2006 Jul; 24(21):3340-6. PubMed ID: 16785471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
    Kimura H; Kasahara K; Shibata K; Sone T; Yoshimoto A; Kita T; Ichikawa Y; Waseda Y; Watanabe K; Shiarasaki H; Ishiura Y; Mizuguchi M; Nakatsumi Y; Kashii T; Kobayashi M; Kunitoh H; Tamura T; Nishio K; Fujimura M; Nakao S
    J Thorac Oncol; 2006 Mar; 1(3):260-7. PubMed ID: 17409866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [EGFR gene mutation statuses in advanced non-small cell lung cancer patients and their influence on effect of gefitinib].
    Zhong W; Wang M; Li L; Xia Y; Chen M; Zhang L; Zhao J
    Zhongguo Fei Ai Za Zhi; 2012 Sep; 15(9):513-20. PubMed ID: 22989454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.
    Yoshida K; Yatabe Y; Park J; Ogawa S; Park JY; Shimizu J; Horio Y; Matsuo K; Mitsudomi T; Hida T
    J Cancer Res Clin Oncol; 2010 Apr; 136(4):527-35. PubMed ID: 19777258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
    Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
    Mitsudomi T; Morita S; Yatabe Y; Negoro S; Okamoto I; Tsurutani J; Seto T; Satouchi M; Tada H; Hirashima T; Asami K; Katakami N; Takada M; Yoshioka H; Shibata K; Kudoh S; Shimizu E; Saito H; Toyooka S; Nakagawa K; Fukuoka M;
    Lancet Oncol; 2010 Feb; 11(2):121-8. PubMed ID: 20022809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.
    Douillard JY; Ostoros G; Cobo M; Ciuleanu T; McCormack R; Webster A; Milenkova T
    Br J Cancer; 2014 Jan; 110(1):55-62. PubMed ID: 24263064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.
    Zhou Q; Zhang XC; Chen ZH; Yin XL; Yang JJ; Xu CR; Yan HH; Chen HJ; Su J; Zhong WZ; Yang XN; An SJ; Wang BC; Huang YS; Wang Z; Wu YL
    J Clin Oncol; 2011 Aug; 29(24):3316-21. PubMed ID: 21788562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
    Paz-Ares L; Tan EH; O'Byrne K; Zhang L; Hirsh V; Boyer M; Yang JC; Mok T; Lee KH; Lu S; Shi Y; Lee DH; Laskin J; Kim DW; Laurie SA; Kölbeck K; Fan J; Dodd N; Märten A; Park K
    Ann Oncol; 2017 Feb; 28(2):270-277. PubMed ID: 28426106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
    Shukuya T; Takahashi T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Takahashi K; Yamamoto N
    Cancer Sci; 2011 May; 102(5):1032-7. PubMed ID: 21272159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
    Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
    Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer.
    Jian G; Songwen Z; Ling Z; Qinfang D; Jie Z; Liang T; Caicun Z
    J Cancer Res Clin Oncol; 2010 Sep; 136(9):1341-7. PubMed ID: 20155428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib for advanced non-small cell lung cancer.
    Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
    Ichihara E; Hotta K; Nogami N; Kuyama S; Kishino D; Fujii M; Kozuki T; Tabata M; Harada D; Chikamori K; Aoe K; Ueoka H; Hosokawa S; Bessho A; Hisamoto-Sato A; Kubo T; Oze I; Takigawa N; Tanimoto M; Kiura K
    J Thorac Oncol; 2015 Mar; 10(3):486-91. PubMed ID: 25695221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.